RecruitingPhase 1NCT07626515

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Enicepatide in Adult Chinese Participants With Body Mass Index ≥23.0 kg/m2

Sponsor

Hoffmann-La Roche

Enrollment

36 participants

Start Date

Jul 2, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Participants

Summary

This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m\^2).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Enicepatide and Placebo for people with healthy participants. The study is currently recruiting participants at 1 location. People eligible for this study include aged {"Phase 1"} to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTEnicepatide

Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.

COMBINATION_PRODUCTPlacebo

Participants will receive matching placebo via subcutaneous (SC) injection as per the schedule in the protocol.

Locations(1)

Peking University First Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07626515

Related Trials

Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance

NCT07769489

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

NCT07793019

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT075112053 locations

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

NCT07751250

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT075390901 location